Persistent losses as upfront investment and R&D expenses precede revenue generation
First written in FY2017-Q1. 22 of 37 entries say "Worsened", first in FY2017-Q2. Latest entry: 2026-08-13.
ReproCELL moved to the "Worse" side of this theme in 2026.
0 other companies' latest entry also says "Worsened".
- 2026-08-13WorsenedEarnings
「As a result, revenue was ¥546 million, up 14.9% year on year; the operating loss was ¥310 million, compared with a loss of ¥291 million in the same quarter of the previous year; the ordinary loss was ¥149 million, compared with a loss of ¥301 million; and the quarterly net loss attributable to owners of the parent was ¥149 million, compared with a loss of ¥304 million.」
Ongoing operating losses continued, and the operating loss widened from the same period of the previous year. Meanwhile, the ordinary loss and quarterly net loss narrowed. - FY2026WorsenedAnnual report
「The company has continued to incur operating losses because research and development expenses and clinical trial expenses for iPS cells and regenerative medicine products, among other items, are incurred ahead of revenue, and events or circumstances exist that raise substantial doubt about the going-concern assumption.」
In FY2026, net sales were ¥2,233 million, the operating loss was ¥860 million, the ordinary loss was ¥581 million and the net loss attributable to owners of the parent was ¥591 million, worsening the loss-leading situation from the previous fiscal year, when the operating loss was ¥130 million, ordinary profit was ¥45 million and net income was ¥103 million. - FY2026-H1WorsenedAnnual report
「As a result, for the six-month consolidated period, consolidated results were net sales of ¥974 million, down 26.2% year on year; an operating loss of ¥546 million, compared with a loss of ¥149 million in the same period of the previous year; an ordinary loss of ¥483 million, compared with a loss of ¥103 million; and an interim net loss attributable to owners of the parent of ¥486 million, compared with a loss of ¥104 million.」
Amid continuing recurring operating losses, net sales declined, and the operating loss, ordinary loss and interim net loss all widened from the same period of the previous year. - FY2025MitigatedAnnual report
「As a result, for the fiscal year, consolidated results were net sales of ¥2,978 million, up 22.7% year on year; an operating loss of ¥130 million, compared with a loss of ¥409 million in the previous fiscal year; ordinary profit of ¥45 million, up 12.1% year on year; and net income attributable to owners of the parent of ¥103 million, compared with a loss of ¥31 million in the previous fiscal year.」
Although recurring operating losses remain, net sales increased 22.7% and the operating loss narrowed from ¥409 million to ¥130 million. Ordinary profit and net income attributable to owners of the parent returned to positive territory, and the loss-leading situation improved on a numerical basis. - FY2025-H1MitigatedAnnual report
「As a result, for the six-month consolidated period, consolidated results were net sales of ¥1,320 million, up 15.1% year on year; an operating loss of ¥149 million, compared with a loss of ¥241 million in the same period of the previous year; an ordinary loss of ¥103 million, compared with profit of ¥70 million; and an interim net loss attributable to owners of the parent of ¥104 million, compared with profit of ¥60 million.」
The operating loss narrowed from ¥241 million in the same period of the previous year to ¥149 million, while net sales also increased 15.1%, resulting in an improvement in operating results. However, ordinary income and interim net income turned from profit in the same period of the previous year to losses, and recurring operating losses and material uncertainty regarding the going-concern assumption remain. - FY2024WorsenedAnnual report
「As a result, for the fiscal year, consolidated results were net sales of ¥2,426 million, down 17.8% year on year; an operating loss of ¥409 million, compared with a loss of ¥356 million in the previous fiscal year; ordinary profit of ¥40 million, compared with a loss of ¥119 million; and a net loss attributable to owners of the parent of ¥31 million, compared with a loss of ¥305 million.」
Although ordinary profit returned to positive territory and the net loss narrowed, net sales declined and the operating loss widened from ¥356 million in the previous fiscal year to ¥409 million. The risk associated with recurring operating losses worsened in terms of operating results. - FY2024-Q3WorsenedAnnual report
「As a result, for the nine-month period of the fiscal year, consolidated results were net sales of ¥1,776 million, down 20.1% year on year; an operating loss of ¥289 million, compared with a loss of ¥207 million in the same period of the previous year; ordinary profit of ¥58 million, compared with a loss of ¥36 million; and net income attributable to owners of the parent of ¥48 million, compared with a loss of ¥39 million.」
Although the company posted ordinary profit and net income attributable to owners of the parent for the quarter, net sales fell 20.1% year on year and the operating loss widened from ¥207 million to ¥289 million, indicating a deterioration in the recurring operating loss position. - FY2024-Q2WorsenedAnnual report
「The company has continued to incur operating losses because research and development expenses and clinical trial expenses for iPS cells and regenerative medicine products, among other items, are incurred ahead of revenue, and events or circumstances exist that raise substantial doubt about the going-concern assumption.」
Recurring operating losses and material uncertainty regarding the going-concern assumption continue. The operating loss for the six-month period was ¥241 million, widening from ¥90 million in the same period of the previous year. - FY2024-Q1WorsenedAnnual report
「We have continued to incur operating losses because research and development and clinical trial expenses for iPS cells and cell-based pharmaceuticals have been incurred ahead of revenue generation, among other reasons, and events or circumstances exist that raise substantial doubt about the going-concern assumption.」
Recurring operating losses and material uncertainty regarding the going-concern assumption remain. The operating loss for the first quarter was ¥124 million, widening from ¥86 million in the same period of the previous year. - FY2023MitigatedAnnual report
「As a result, for the fiscal year, consolidated results were net sales of ¥2,953 million, up 32.2% year on year; an operating loss of ¥356 million, compared with a loss of ¥647 million in the previous fiscal year; an ordinary loss of ¥119 million, compared with a loss of ¥507 million; and a net loss attributable to owners of the parent of ¥305 million, compared with a loss of ¥575 million.」
Although recurring operating losses remain, net sales increased 32.2%, and the operating loss, ordinary loss and net loss attributable to owners of the parent all narrowed from the previous fiscal year. - FY2023-Q3MitigatedAnnual report
「As a result, for the nine-month period of the fiscal year, consolidated results were net sales of ¥2,223 million, up 49.4% year on year; an operating loss of ¥207 million, compared with a loss of ¥529 million in the same period of the previous year; an ordinary loss of ¥36 million, compared with a loss of ¥351 million; and a net loss attributable to owners of the parent of ¥39 million, compared with a loss of ¥351 million.」
While recurring operating losses and material uncertainty regarding the going-concern assumption remain, net sales increased 49.4% year on year, and the operating loss, ordinary loss and net loss attributable to owners of the parent for the quarter all narrowed substantially from the same period of the previous year. - FY2023-Q2MitigatedAnnual report
「As a result, for the six months ended the second quarter, revenue was ¥1,576 million, up 59.4% year on year, operating loss was ¥90 million, compared with a loss of ¥359 million in the same period of the previous year, ordinary profit was ¥70 million, compared with a loss of ¥201 million, and quarterly net profit attributable to owners of the parent was ¥68 million, compared with a loss of ¥201 million.」
Operating loss narrowed from ¥359 million in the same period of the previous year to ¥90 million, while the company posted ordinary profit of ¥70 million and net income attributable to owners of the parent of ¥68 million. Although recurring operating losses remain, the loss-leading situation has improved on a numerical basis. - FY2023-Q1MitigatedAnnual report
「We have continued to incur operating losses because research and development and clinical trial expenses for iPS cells and cell-based pharmaceuticals have been incurred ahead of revenue generation, among other reasons, and events or circumstances exist that raise substantial doubt about the going-concern assumption. However, the balance of cash and deposits held by the Group at the end of the first quarter was ¥4,198 million, and securities held for short-term fund management amounted to ¥970 million, indicating a stable financial position.」
Although recurring operating losses and substantial doubt about the going-concern assumption remained, operating loss decreased from ¥276 million in the same period of the previous year to ¥86 million, and the Company recorded ordinary profit of ¥42 million. - FY2022-Q3MitigatedAnnual report
「As a result, for the nine months ended the third quarter, revenue was ¥1,488 million, up 56.8% year on year, operating loss was ¥529 million, compared with a loss of ¥764 million in the same period of the previous year, ordinary loss was ¥351 million, compared with a loss of ¥657 million, and quarterly net loss attributable to owners of the parent was ¥351 million, compared with a loss of ¥658 million.」
Operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all decreased from the same period of the previous year, while revenue increased 56.8% year on year. However, operating losses continued. - FY2022-Q2MitigatedAnnual report
「As a result, for the six months ended the second quarter, revenue was ¥989 million, up 60.8% year on year, operating loss was ¥359 million, compared with a loss of ¥502 million in the same period of the previous year, ordinary loss was ¥201 million, compared with a loss of ¥365 million, and quarterly net loss attributable to owners of the parent was ¥201 million, compared with a loss of ¥365 million.」
Operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all decreased from the same period of the previous year, while revenue increased 60.8% year on year. However, operating losses continued. - FY2022-Q1MitigatedAnnual report
「We have continued to incur operating losses because research and development and clinical trial expenses for iPS cells and cell-based pharmaceuticals have been incurred ahead of revenue generation, among other reasons, and events or circumstances exist that raise substantial doubt about the going-concern assumption.」
Although recurring operating losses continued, operating loss for the first quarter decreased to ¥276 million from ¥289 million in the same period of the previous year, and ordinary loss also decreased to ¥122 million. - FY2021WorsenedAnnual report
「As a result, revenue for the fiscal year was ¥1,286 million, up 7.2% year on year, operating loss was ¥1,048 million, compared with a loss of ¥908 million in the previous fiscal year, ordinary loss was ¥788 million, compared with a loss of ¥891 million, and net loss attributable to owners of the parent was ¥812 million, compared with a loss of ¥1,016 million.」
Although revenue, ordinary loss and net loss improved, operating loss increased from ¥908 million to ¥1,048 million, indicating a deterioration in the continuing situation in which losses precede revenue in terms of operating results. - FY2021-Q3WorsenedAnnual report
「As a result, for the nine months ended the third quarter, revenue was ¥949 million, up 6.5% year on year, operating loss was ¥764 million, compared with a loss of ¥671 million in the same period of the previous year, ordinary loss was ¥657 million, compared with a loss of ¥656 million, and quarterly net loss attributable to owners of the parent was ¥658 million, compared with a loss of ¥663 million.」
Although revenue increased 6.5% year on year, operating loss increased from ¥671 million to ¥764 million, indicating a deterioration in the continuing situation in which losses precede revenue in terms of operating results. - FY2021-Q2WorsenedAnnual report
「As a result, for the six months ended the second quarter, revenue was ¥614 million, up 8.9% year on year, operating loss was ¥502 million, compared with a loss of ¥432 million in the same period of the previous year, ordinary loss was ¥365 million, compared with a loss of ¥434 million, and quarterly net loss attributable to owners of the parent was ¥365 million, compared with a loss of ¥436 million.」
Although revenue increased 8.9% year on year and ordinary loss and net loss decreased, operating loss increased from ¥432 million to ¥502 million, indicating a deterioration in the continuing situation in which losses precede revenue in terms of operating results. - FY2021-Q1WorsenedAnnual report
「As a result, for the first quarter of the fiscal year, revenue was ¥168 million, down 34.5% year on year, operating loss was ¥289 million, compared with a loss of ¥225 million in the same period of the previous year, ordinary loss was ¥207 million, compared with a loss of ¥229 million, and quarterly net loss attributable to owners of the parent was ¥208 million, compared with a loss of ¥229 million.」
Revenue declined 34.5% year on year, and operating loss increased from ¥225 million to ¥289 million. Although ordinary loss and quarterly net loss attributable to owners of the parent decreased, the risk that losses precede revenue deteriorated in terms of operating results and revenue. - FY2020WorsenedAnnual report
「As a result, revenue for the fiscal year was ¥1,199 million, up 10.2% year on year, operating loss was ¥908 million, compared with a loss of ¥781 million in the previous fiscal year, ordinary loss was ¥891 million, compared with a loss of ¥627 million, and net loss attributable to owners of the parent was ¥1,016 million, compared with a loss of ¥601 million.」
Although revenue increased, operating loss, ordinary loss and net loss attributable to owners of the parent all increased from the previous fiscal year, indicating a deterioration in the numerical indicators of the risk that losses precede revenue. - FY2020-Q3WorsenedAnnual report
「As a result, for the nine months ended the third quarter, revenue was ¥891 million, up 10.6% year on year, operating loss was ¥671 million, compared with a loss of ¥587 million in the same period of the previous year, ordinary loss was ¥656 million, compared with a loss of ¥456 million, and quarterly net loss attributable to owners of the parent was ¥663 million, compared with a loss of ¥430 million.」
Although revenue increased 10.6% year on year, operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all increased from the same period of the previous year, indicating a deterioration in the numerical indicators of the situation in which losses precede revenue. - FY2020-Q2WorsenedAnnual report
「As a result, for the six months ended the second quarter, revenue was ¥564 million, up 4.8% year on year, operating loss was ¥432 million, compared with a loss of ¥405 million in the same period of the previous year, ordinary loss was ¥434 million, compared with a loss of ¥251 million, and quarterly net loss attributable to owners of the parent was ¥436 million, compared with a loss of ¥228 million.」
Although revenue increased 4.8% year on year, operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all increased from the same period of the previous year, indicating a deterioration in the numerical indicators of the situation in which losses precede revenue. - FY2020-Q1WorsenedAnnual report
「As a result, for the first quarter of the fiscal year, revenue was ¥256 million, up 0.8% year on year, operating loss was ¥225 million, compared with a loss of ¥221 million in the same period of the previous year, ordinary loss was ¥229 million, compared with a loss of ¥97 million, and quarterly net loss attributable to owners of the parent was ¥229 million, compared with a loss of ¥80 million.」
Recurring operating losses continued, with operating loss increasing from the same period of the previous year. Ordinary loss and quarterly net loss attributable to owners of the parent also increased substantially year on year, indicating a deterioration in the numerical indicators of the situation in which losses precede revenue. - FY2019-Q3MitigatedAnnual report
「As a result, for the nine months ended the third quarter, revenue was ¥806 million, up 17.3% year on year, operating loss was ¥587 million, compared with a loss of ¥772 million in the same period of the previous year, ordinary loss was ¥456 million, compared with a loss of ¥639 million, and quarterly net loss attributable to owners of the parent was ¥430 million, compared with a loss of ¥652 million.」
Although losses continued, revenue increased 17.3% year on year, while operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all decreased from the same period of the previous year. - FY2019-Q2MitigatedAnnual report
「As a result, for the six months ended the second quarter, revenue was ¥538 million, up 20.8% year on year, operating loss was ¥405 million, compared with a loss of ¥536 million in the same period of the previous year, ordinary loss was ¥251 million, compared with a loss of ¥416 million, and quarterly net loss attributable to owners of the parent was ¥228 million, compared with a loss of ¥435 million.」
Although losses continued, revenue increased 20.8% year on year, while operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all decreased from the same period of the previous year. - FY2019-Q1MitigatedAnnual report
「As a result, for the first quarter of the fiscal year, revenue was ¥254 million, up 20.6% year on year, operating loss was ¥221 million, compared with a loss of ¥274 million in the same period of the previous year, ordinary loss was ¥97 million, compared with a loss of ¥196 million, and net loss attributable to owners of the parent was ¥80 million, compared with a loss of ¥200 million.」
Although losses continued, revenue increased 20.6% year on year, while operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all decreased from the same period of the previous year. - FY2018WorsenedAnnual report
「As a result, revenue for the fiscal year was ¥926 million, down 26.4% year on year, operating loss was ¥1,025 million, compared with a loss of ¥944 million in the previous fiscal year, ordinary loss was ¥935 million, compared with a loss of ¥937 million, and net loss attributable to owners of the parent was ¥2,172 million, compared with a loss of ¥911 million.」
Recurring operating losses continued, with operating loss increasing from ¥944 million to ¥1,025 million. Revenue also declined 26.4% year on year, and net loss increased partly because of impairment losses. - FY2018-Q3WorsenedAnnual report
「As a result, revenue for the nine months ended the third quarter was ¥686.968 million, down 20.2% year on year, operating loss was ¥772.402 million, compared with a loss of ¥624.062 million in the same period of the previous year, ordinary loss was ¥639.055 million, compared with a loss of ¥565.113 million, and net loss attributable to owners of the parent was ¥652.194 million, compared with a loss of ¥544.112 million.」
Losses continued, with operating loss increasing from ¥624.062 million to ¥772.402 million and ordinary loss increasing from ¥565.113 million to ¥639.055 million year on year. Revenue also declined 20.2% year on year. - FY2018-Q1WorsenedAnnual report
「As a result, revenue for the first quarter of the fiscal year was ¥211.048 million, down 20.7% year on year, operating loss was ¥274.633 million, compared with a loss of ¥245.684 million in the same quarter of the previous year, and ordinary loss was ¥196.875 million, compared with a loss of ¥352.444 million in the same quarter of the previous year.」
Recurring operating losses continued, with operating loss increasing from ¥245.684 million in the same quarter of the previous year to ¥274.633 million. Ordinary loss, however, decreased from the same period of the previous year, mainly because of foreign exchange gains. - FY2017MitigatedAnnual report
「We have continued to incur operating losses because amortization of goodwill and intangible assets arising from the acquisition of overseas subsidiaries, as well as research and development and clinical trial expenses for iPS cells and cell-based pharmaceuticals, have been incurred ahead of revenue generation, among other reasons.」
Although recurring operating losses continued, operating loss decreased to ¥944 million from ¥1,024 million in the same period of the previous year. - FY2017-Q3MitigatedAnnual report
「We have continued to incur operating losses because of upfront investment to establish a global sales network and because research and development expenses for iPS cells and regenerative medicine have been incurred ahead of revenue generation, among other reasons.」
Although recurring operating losses continued, operating loss for the nine months ended the third quarter decreased to ¥624.062 million from ¥710.467 million in the same period of the previous year. - FY2017-Q2WorsenedAnnual report
「We have continued to incur operating losses because of upfront investment to establish a global sales network and because research and development expenses for iPS cells and regenerative medicine have been incurred ahead of revenue generation, among other reasons.」
Recurring operating losses continued, with operating loss for the six months ended the second quarter reaching ¥469.183 million and ordinary loss reaching ¥601.974 million. The risk persisted, and the losses increased year on year. - FY2017-Q1First statedAnnual report
「We have continued to incur operating losses because of upfront investment to establish a global sales network and because research and development expenses for iPS cells and regenerative medicine have been incurred ahead of revenue generation, among other reasons.」
The Company recorded an operating loss of ¥245.684 million and an ordinary loss of ¥352.444 million in the quarter, confirming that the stated losses had actually occurred.